Table 2.
Distribution of physician specialties and prescription patterns of anti‐hyperglycaemic agents in study patients
| Year |
2016 (n = 319) |
2017 (n = 340) |
2018 (n = 324) |
P value |
|---|---|---|---|---|
| Numbers of anti‐hyperglycaemic agents prescribed | 2.1 ± 1.0 | 2.1 ± 1.0 | 2.1 ± 1.0 | 0.712 |
| Physicians who prescribe anti‐hyperglycaemic agents, n (%) | ||||
| Cardiologists | 135 (42.3) | 157 (46.2) | 152 (46.9) | 0.778 |
| Endocrinologists | 102 (32.0) | 99 (29.1) | 97 (29.9) | |
| Others | 82 (25.7) | 84 (24.7) | 75 (23.1) | |
| Prescribed anti‐hyperglycaemic agents, n (%) | ||||
| Metformin | 159 (49.8) | 179 (52.6) | 184 (56.8) | 0.206 |
| SGLT2i | 33 (10.3) | 60 (17.6) | 86 (26.5) | <0.001 |
| DPP4i | 157 (49.2) | 164 (48.2) | 138 (42.6) | 0.189 |
| SU | 156 (48.9) | 158 (46.5) | 142 (43.8) | 0.435 |
| AGI | 71 (22.3) | 66 (19.4) | 62 (19.1) | 0.551 |
| Insulin | 63 (19.7) | 69 (20.3) | 68 (21.0) | 0.926 |
| TZD | 4 (1.3) | 7 (2.1) | 6 (1.9) | 0.715 |
AGI, alpha‐glucosidase inhibitor; DPP4i, dipeptidyl peptidase‐4 inhibitor; SGLT2i, sodium‐glucose co‐transporter‐2 inhibitor; SU, sulfonylurea; TZD, thiazolidinedione.